Andrew Bateman

1.7k total citations
30 papers, 1.1k citations indexed

About

Andrew Bateman is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Andrew Bateman has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Surgery and 13 papers in Oncology. Recurrent topics in Andrew Bateman's work include Virus-based gene therapy research (10 papers), RNA Interference and Gene Delivery (10 papers) and Esophageal Cancer Research and Treatment (10 papers). Andrew Bateman is often cited by papers focused on Virus-based gene therapy research (10 papers), RNA Interference and Gene Delivery (10 papers) and Esophageal Cancer Research and Treatment (10 papers). Andrew Bateman collaborates with scholars based in United Kingdom, United States and Netherlands. Andrew Bateman's co-authors include Richard G. Vile, Alan Melcher, Emmanouela Linardakis, Kevin J. Harrington, Stephen Todryk, Mario P. Colombo, Adrian C Bateman, Antonella Stoppacciaro, Nicola Hardwick and Eleanor Jaynes and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Clinical Cancer Research.

In The Last Decade

Andrew Bateman

30 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Bateman United Kingdom	16	449	417	363	332	288	30	1.1k
Lihua Tao United States	21	627 1.4×	541 1.3×	534 1.5×	281 0.8×	81 0.3×	51	1.3k
J. Andrea McCart Canada	17	722 1.6×	480 1.2×	1.1k 3.0×	256 0.8×	183 0.6×	35	1.5k
Patricia C. Ryan United States	19	372 0.8×	495 1.2×	363 1.0×	299 0.9×	52 0.2×	32	1.3k
Howard Goldsweig United States	11	661 1.5×	444 1.1×	507 1.4×	270 0.8×	77 0.3×	19	1.1k
J. Andrea McCart Canada	15	608 1.4×	343 0.8×	759 2.1×	161 0.5×	99 0.3×	22	1.1k
Polly R. Etkind United States	19	221 0.5×	548 1.3×	295 0.8×	245 0.7×	100 0.3×	30	1.2k
Karen J. Scott United Kingdom	20	657 1.5×	314 0.8×	628 1.7×	427 1.3×	30 0.1×	33	1.2k
Ariel C. Hollinshead United States	20	466 1.0×	303 0.7×	207 0.6×	533 1.6×	73 0.3×	70	1.2k
Matthew J. Atherton United States	14	237 0.5×	142 0.3×	285 0.8×	194 0.6×	50 0.2×	35	685
Manuel E. Engelhorn United States	14	419 0.9×	376 0.9×	229 0.6×	946 2.8×	39 0.1×	19	1.3k

Countries citing papers authored by Andrew Bateman

Since Specialization

Citations

This map shows the geographic impact of Andrew Bateman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Bateman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Bateman more than expected).

Fields of papers citing papers by Andrew Bateman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Bateman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Bateman. The network helps show where Andrew Bateman may publish in the future.

Co-authorship network of co-authors of Andrew Bateman

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Bateman. A scholar is included among the top collaborators of Andrew Bateman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Bateman. Andrew Bateman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ewings, Sean, Nadia Peppa, Daniel E. Griffiths, et al.. (2025). The ELECTRA Trial: Approach to Contemporary Challenges in the Development and Implementation of Double-Blinded, Randomised, Controlled Clinical Trials in Low-Volume High-Complexity Surgical Oncology. Cancers. 17(3). 341–341. 1 indexed citations

Ryder, David, et al.. (2023). Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study. Clinical and Translational Radiation Oncology. 40. 100614–100614. 7 indexed citations

Mukherjee, Somnath, Chris Hurt, Ganesh Radhakrishna, et al.. (2021). Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer. 153. 153–161. 13 indexed citations

Pucher, Philip H., Saqib Rahman, Robert Walker, et al.. (2020). Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. European Journal of Surgical Oncology. 46(12). 2248–2256. 19 indexed citations

Mukherjee, Somnath, Chris Hurt, Sarah Gwynne, et al.. (2017). NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer. 74. 38–46. 32 indexed citations

Noble, Fergus, Toby Mellows, Adrian C Bateman, et al.. (2016). Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunology Immunotherapy. 65(6). 651–662. 82 indexed citations

Mukherjee, Somnath, Chris Hurt, Sarah Gwynne, et al.. (2016). NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.. Journal of Clinical Oncology. 34(4_suppl). 3–3. 3 indexed citations

Sclafani, Francesco, Clare Peckitt, David Cunningham, et al.. (2015). Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. International Journal of Radiation Oncology*Biology*Physics. 93(2). 303–312. 18 indexed citations

Mukherjee, Somnath, Chris Hurt, Sarah Gwynne, et al.. (2015). NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer. 15(1). 48–48. 25 indexed citations

10.

Noble, Fergus, James Hopkins, Nathan Curtis, et al.. (2013). The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Medical Oncology. 30(3). 596–596. 39 indexed citations

11.

King, Catherine, et al.. (2012). Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk. OncoImmunology. 1(6). 874–883. 8 indexed citations

12.

Bateman, Adrian C, Eleanor Jaynes, & Andrew Bateman. (2009). Rectal cancer staging post neoadjuvant therapy – how should the changes be assessed?. Histopathology. 54(6). 713–721. 57 indexed citations

13.

Errington‐Mais, Fiona, Andrew Bateman, Tim Kottke, et al.. (2006). Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.. Clinical Cancer Research. 12(4). 1333–1341. 24 indexed citations

14.

Lysaght, Joanne, et al.. (2003). Heat shock protein derived from a non‐autologous tumour can be used as an anti‐tumour vaccine. Immunology. 110(1). 105–111. 18 indexed citations

15.

Melcher, Alan, Andrew Bateman, Kevin J. Harrington, et al.. (2002). Dendritic Cells for the Immunotherapy of Cancer. Clinical Oncology. 14(3). 185–192. 4 indexed citations

16.

Harrington, Kevin J., Andrew Bateman, Alan Melcher, Atique U. Ahmed, & Richard G. Vile. (2002). Cancer Gene Therapy: Part 1. Vector Development and Regulation of Gene Expression. Clinical Oncology. 14(1). 3–16. 9 indexed citations

17.

Harrington, Kevin J., Alan Melcher, Andrew Bateman, Atique U. Ahmed, & Richard G. Vile. (2002). Cancer Gene Therapy: Part 2. Candidate Transgenes and their Clinical Development. Clinical Oncology. 14(2). 148–169. 7 indexed citations

18.

Kirkham, Lucy, Andrew Bateman, Alan Melcher, Richard G. Vile, & Adele K. Fielding. (2002). Lack of specificity of cell‐surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein. The Journal of Gene Medicine. 4(6). 592–600. 4 indexed citations

19.

Galanis, Evanthia, Andrew Bateman, K.A. Johnson, et al.. (2001). Use of Viral Fusogenic Membrane Glycoproteins as Novel Therapeutic Transgenes in Gliomas. Human Gene Therapy. 12(7). 811–821. 85 indexed citations

20.

Todryk, Stephen, Alan Melcher, Nicola Hardwick, et al.. (1999). Heat Shock Protein 70 Induced During Tumor Cell Killing Induces Th1 Cytokines and Targets Immature Dendritic Cell Precursors to Enhance Antigen Uptake. The Journal of Immunology. 163(3). 1398–1408. 265 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact